3Oran NT, Oran I, Memis A. Management of patients with malignant obstructive jaundice [J]. Cancer Nursing,2000,23(2):128-133.
二级参考文献9
1Koretz RL.Nutritonal support: how much for how much? Gut, 1986,217 supp1∶85.
2孙燕,周际昌主编.《临床肿瘤内科手册》.第3版.北京:人民卫生出版社,1996.53-54.
3Dreizen S, Mccredie KB, Keating MJ, et al. Nutritional dificiencies in patients receiving cancer chemotherapy. Postgrad Med, 1990, 87:163.
4Samlowski, Wiebke G, McMurry M, et al.Effects TPN during high-dose interleukin-2 trestment for metastatic cancer.Jlmmunotjer,1998,21:65-74.
5Kollmannsberger C, Peters H D, Fink V. Chemotherapy in advanced panceratic adenocarcinoma. Cancer treat Rev, 1998,24:133-156.
6William J, Melissa Q. Continuous Venous infusion 5-Fu and interferon-a in pancreatic carcinoma. Am J Clin Oncol, 1998,21:147.
7Basile M,Rougier P,Ducreux M, et al. A phase Ⅱ study of 5-FU continous infusion and CDDP in measurable advanced carcioma of the pancreas. Porc Am. Soc Clin Oncol, 1991, 10:149(abstract 461).
8Weinerman B, Mac Cormick R. A phase Ⅱ survival comparison of patients with adenocarcinoma of the pancreas treated with 5-FU and calcium leucovorin versus a matched tumor vegistry control population. Am J Clin Oncol, 1994,17:467-469.
9Munzone E, Nole F, de Brand F. ECF in pancereatic carcimoma: a promising approach. Proc Am Soc Clin Oncol,1997,16:298a (abstract 1062).
